Clinical trial NCT04053634: Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Official title: A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Chronic Obstructive Pulmonary Disease
COPD
benralizumab
Fasenra
ICS
inhaled corticosteroids
exacerbations
Lung Disease
LABA/LAMA
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2019-08-12
Enrollment: 689
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).

Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count.

The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.


Eligibility criteria: Inclusion Criteria:

1. Provision of informed consent
2. Age 40 to 85 years
3. Male and/or female.
4. Current or former smoker with a tobacco history of ≥10 pack-years.
5. History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC\<0.70 and FEV1 ≤65% of predicted normal value.
6. Documented history of 2 or more COPD exacerbations that required treatment with systemic corticosteroids and/or hospitalization within 52 weeks prior to enrollment.

   1. Exacerbations treated with antibiotics alone are excluded unless accompanied by treatment with systemic corticosteroids and/or hospitalization.
   2. Hospitalization is defined as an inpatient admission ≥24 hours
   3. Previous exacerbations should be confirmed to have occurred while on stable triple therapy for COPD.
   4. At least one qualifying COPD exacerbation should occur while on stable uninterrupted triple therapy prior to enrolment.
7. Documented use of triple (ICS/LABA/LAMA) background therapy for COPD for ≥3 months immediately prior to enrollment.

   1. Treatment with at least double inhaled therapy containing ICS (e.g. ICS/LABA or ICS/LAMA) for the remaining of 52 weeks prior to enrolment. Use of LABA/LAMA is allowed if ICS cannot be tolerated.
   2. ICS in a dose approved for COPD or equivalent to ≥250 mcg of fluticasone propionate daily.
   3. Total cumulative duration of not being on double or triple background therapy must not exceed 2 months.
   4. Stable therapy/doses for the last 3 months prior to randomization.
8. Blood eosinophil count ≥300/μL at screening and documented historical eosinophil count of ≥150/μL within 52 weeks of enrollment (or repeated testing during run-in).
9. CAT total score ≥15 at Visit 1.
10. Negative pregnancy test for females of childbearing potential (WOCBP) at Visit 1.
11. Women of childbearing potential (WOCBP) must agree to use a highly effective method of birth control from enrollment throughout the study and within 12 weeks after last dose of IP.

Women not of childbearing potential are defined as women who are either permanently sterilized or postmenopausal (confirmed by FSH test for women \<50 years).

Exclusion Criteria:

1. Clinically important pulmonary disease other than COPD
2. Current diagnosis of asthma, prior history of asthma or asthma-COPD overlap according to GINA/GOLD. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
3. Radiological findings of a respiratory disease other than COPD contributing to respiratory symptoms. Solitary pulmonary nodules without appropriate follow up or findings of acute infection.
4. Another pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
5. Any unstable disorder that could affect patient safety, study findings or the patient's ability to complete the study.
6. Any clinically significant abnormal findings in physical examination, vital signs, ECG, laboratory tests could affect patient safety, study findings or the patient's ability to complete the study.
7. Cor pulmonale and/or right ventricular failure.
8. Long-term treatment with oxygen \>4.0 L/min and/or oxyhemoglobin saturation \<89% while breathing supplemental oxygen.
9. Use of any non-invasive positive pressure ventilation device (NIPPV). Note: use of CPAP for Sleep Apnea Syndrome is allowed.
10. Known immunodeficiency disorder, including positive HIV-1/2 testing.
11. Active liver disease. Chronic stable hepatitis B and C (including positive HBsAg or hepatitis C antibody testing), or other stable chronic liver disease are acceptable.
12. ALT or AST ≥3 times the upper limit of normal, confirmed by repeated testing during the run-in period.
13. Helminth parasitic infection within 24 weeks prior to enrollment, not treated or failed to respond to standard of care therapy.
14. Alcohol or drug abuse within the past year, which may compromise the study data.
15. Malignancy, current or within the past 5 years, except for adequately treated non invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1. Suspected malignancy or undefined neoplasms.
16. Evidence of active tuberculosis, as judged by investigator. Patients with a recent (within 2 years) first-time or newly positive PPD or Quantiferon test need to complete an appropriate course of treatment before enrollment. Evaluation will be according to the local standard of care.
17. Participation, or planned participation, in intensive COPD rehabilitation program (maintenance phase of a rehabilitation is allowed).
18. History of surgical or endoscopic lung volume reduction within the 6 months prior to enrollment. History of partial or total lung resection (single lobe or segmentectomy is acceptable).
19. Scheduled major surgical procedure during the study. Minor elective procedures are allowed.
20. History of anaphylaxis to any biologic therapy or vaccine.
21. Receipt of blood products or immunoglobulins within 30 days prior to randomization.
22. Receipt of marketed or investigational biologic product within 4 months or 5 half-lives prior to randomization, whichever is longer. Exception: Patients on stable therapy for 3 months before randomization who intend to stay on treatment throughout the study with marketed biologic products that are not likely to interfere with the safety assessment and/or efficacy of benralizumab, for example, for the treatment of osteoporosis, migraine, pain, diabetes, obesity, ocular, cardiovascular, or metabolic diseases, can participate in the study.
23. Receipt of live attenuated vaccines 30 days prior to randomization.
24. Chronic use of immunosuppressive medication or expected need for chronic use during the study.
25. Chronic use of antibiotics if duration of treatment is \<9 months prior to randomization. Chronic macrolide or other antibiotic therapy is allowed provided the patient has been on stable dose/regimen for ≥9 months prior to randomization and has had ≥2 COPD exacerbations while on stable therapy.
26. Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to enrollment.
27. Receipt of benralizumab within 12 months prior to enrollment.
28. Known history of allergy or reaction to any component of the IP formulation.

Primary outcomes:
measure: Annualized rate of moderate or severe COPD exacerbations
timeFrame: Over first 56 weeks
Secondary outcomes:
measure: Annualized rate of severe COPD exacerbations
timeFrame: Minimum of 1 year and an average of 2 years
measure: Annualized rate of COPD exacerbations that are associated with an emergency room/emergency department visit or a hospitalization
timeFrame: Minimum of 1 year and an average of 2 years
measure: Time to first COPD exacerbation
timeFrame: During first 56 weeks
measure: Change from baseline in SGRQ total and domain scores
timeFrame: up to 56 weeks
measure: Change from baseline in E-RS:COPD total and domain scores
timeFrame: up to 56 weeks
measure: Change from baseline in pre-dose/pre-bronchodilator FEV1
timeFrame: up to 56 weeks
measure: All cause and respiratory-related mortality rate
timeFrame: Minimum of 1 year and an average of 2 years
measure: Annual rate of hospitalizations due to COPD
timeFrame: Minimum of 1 year and an average of 2 years
measure: Serum benralizumab concentration as a measure of pharmacokinetics
timeFrame: up to 56 weeks
measure: Anti-drug antibodies (ADA) as a measure of immunogenicity
timeFrame: up to 56 weeks
measure: Change from baseline in CAT total score
timeFrame: up to 56 weeks
measure: Length of hospital stay
timeFrame: Minimum of 1 year and an average of 2 years
measure: ICU (Intensive Care Unit) days
timeFrame: Minimum of 1 year and an average of 2 years
measure: Annual rate of hospitalizations and emergency department visits combined
timeFrame: Minimum of 1 year and an average of 2 years
measure: Annual rate of unscheduled outpatient visits including unscheduled visits to study sites
timeFrame: Minimum of 1 year and an average of 2 years
measure: Annual rate of unscheduled healthcare encounters
timeFrame: Minimum of 1 year and and average of 2 years
Other outcomes:
measure: Safety and tolerability of benralizumab in patients with moderate to very severe COPD
timeFrame: Minimum of 1 year and average of 2 years
Locations:
city: Surprise
country: United States
facility: Research Site
state: Arizona
city: Little Rock
country: United States
facility: Research Site
state: Arkansas
city: Los Angeles
country: United States
facility: Research Site
state: California
city: Los Angeles
country: United States
facility: Research Site
state: California
city: Newport Beach
country: United States
facility: Research Site
state: California
city: Northridge
country: United States
facility: Research Site
state: California
city: Palm Springs
country: United States
facility: Research Site
state: California
city: Westminster
country: United States
facility: Research Site
state: California
city: Stamford
country: United States
facility: Research Site
state: Connecticut
city: Clearwater
country: United States
facility: Research Site
state: Florida
city: Daytona Beach
country: United States
facility: Research Site
state: Florida
city: Edgewater
country: United States
facility: Research Site
state: Florida
city: Jacksonville
country: United States
facility: Research Site
state: Florida
city: Jacksonville
country: United States
facility: Research Site
state: Florida
city: Kissimmee
country: United States
facility: Research Site
state: Florida
city: Kissimmee
country: United States
facility: Research Site
state: Florida
city: Leesburg
country: United States
facility: Research Site
state: Florida
city: Miami
country: United States
facility: Research Site
state: Florida
city: Orlando
country: United States
facility: Research Site
state: Florida
city: Pensacola
country: United States
facility: Research Site
state: Florida
city: Saint Petersburg
country: United States
facility: Research Site
state: Florida
city: Tampa
country: United States
facility: Research Site
state: Florida
city: Winter Park
country: United States
facility: Research Site
state: Florida
city: Lawrenceville
country: United States
facility: Research Site
state: Georgia
city: Rincon
country: United States
facility: Research Site
state: Georgia
city: Chicago
country: United States
facility: Research Site
state: Illinois
city: O'Fallon
country: United States
facility: Research Site
state: Illinois
city: Peoria
country: United States
facility: Research Site
state: Illinois
city: Michigan City
country: United States
facility: Research Site
state: Indiana
city: Iowa City
country: United States
facility: Research Site
state: Iowa
city: Kansas City
country: United States
facility: Research Site
state: Kansas
city: Georgetown
country: United States
facility: Research Site
state: Kentucky
city: Baltimore
country: United States
facility: Research Site
state: Maryland
city: Columbia
country: United States
facility: Research Site
state: Maryland
city: Boston
country: United States
facility: Research Site
state: Massachusetts
city: North Dartmouth
country: United States
facility: Research Site
state: Massachusetts
city: Farmington Hills
country: United States
facility: Research Site
state: Michigan
city: Lincoln
country: United States
facility: Research Site
state: Nebraska
city: Omaha
country: United States
facility: Research Site
state: Nebraska
city: Toms River
country: United States
facility: Research Site
state: New Jersey
city: Bronx
country: United States
facility: Research Site
state: New York
city: Buffalo
country: United States
facility: Research Site
state: New York
city: New Windsor
country: United States
facility: Research Site
state: New York
city: Burlington
country: United States
facility: Research Site
state: North Carolina
city: Charlotte
country: United States
facility: Research Site
state: North Carolina
city: Elizabeth City
country: United States
facility: Research Site
state: North Carolina
city: Gastonia
country: United States
facility: Research Site
state: North Carolina
city: Mooresville
country: United States
facility: Research Site
state: North Carolina
city: New Bern
country: United States
facility: Research Site
state: North Carolina
city: Wilmington
country: United States
facility: Research Site
state: North Carolina
city: Winston-Salem
country: United States
facility: Research Site
state: North Carolina
city: Cleveland
country: United States
facility: Research Site
state: Ohio
city: Columbus
country: United States
facility: Research Site
state: Ohio
city: Oklahoma City
country: United States
facility: Research Site
state: Oklahoma
city: Medford
country: United States
facility: Research Site
state: Oregon
city: DuBois
country: United States
facility: Research Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Research Site
state: Pennsylvania
city: Smithfield
country: United States
facility: Research Site
state: Pennsylvania
city: Mount Pleasant
country: United States
facility: Research Site
state: South Carolina
city: North Charleston
country: United States
facility: Research Site
state: South Carolina
city: Rock Hill
country: United States
facility: Research Site
state: South Carolina
city: Rapid City
country: United States
facility: Research Site
state: South Dakota
city: Chattanooga
country: United States
facility: Research Site
state: Tennessee
city: Franklin
country: United States
facility: Research Site
state: Tennessee
city: Hendersonville
country: United States
facility: Research Site
state: Tennessee
city: Johnson City
country: United States
facility: Research Site
state: Tennessee
city: Amarillo
country: United States
facility: Research Site
state: Texas
city: Amarillo
country: United States
facility: Research Site
state: Texas
city: Cypress
country: United States
facility: Research Site
state: Texas
city: Dallas
country: United States
facility: Research Site
state: Texas
city: Fort Worth
country: United States
facility: Research Site
state: Texas
city: Houston
country: United States
facility: Research Site
state: Texas
city: Kerrville
country: United States
facility: Research Site
state: Texas
city: San Antonio
country: United States
facility: Research Site
state: Texas
city: Tomball
country: United States
facility: Research Site
state: Texas
city: Salt Lake City
country: United States
facility: Research Site
state: Utah
city: Abingdon
country: United States
facility: Research Site
state: Virginia
city: Salem
country: United States
facility: Research Site
state: Virginia
city: Williamsburg
country: United States
facility: Research Site
state: Virginia
city: Everett
country: United States
facility: Research Site
state: Washington
city: Spokane
country: United States
facility: Research Site
state: Washington
city: Morgantown
country: United States
facility: Research Site
state: West Virginia
city: Cudahy
country: United States
facility: Research Site
state: Wisconsin
city: Buenos Aires
country: Argentina
facility: Research Site
city: Caba
country: Argentina
facility: Research Site
city: Ciudad Autónoma de Buenos Aire
country: Argentina
facility: Research Site
city: Ciudad de Buenos Aires
country: Argentina
facility: Research Site
city: Córdoba
country: Argentina
facility: Research Site
city: Florencio Varela
country: Argentina
facility: Research Site
city: Florida
country: Argentina
facility: Research Site
city: Mar del Plata
country: Argentina
facility: Research Site
city: Mendoza
country: Argentina
facility: Research Site
city: San Fernando
country: Argentina
facility: Research Site
city: San Miguel de Tucuman
country: Argentina
facility: Research Site
city: Caringbah
country: Australia
facility: Research Site
city: Melbourne
country: Australia
facility: Research Site
city: South Brisbane
country: Australia
facility: Research Site
city: Southport
country: Australia
facility: Research Site
city: Spearwood
country: Australia
facility: Research Site
city: Bad Ischl
country: Austria
facility: Research Site
city: Bludenz
country: Austria
facility: Research Site
city: Feldbach
country: Austria
facility: Research Site
city: Grieskirchen
country: Austria
facility: Research Site
city: Linz
country: Austria
facility: Research Site
city: Thalheim
country: Austria
facility: Research Site
city: Edegem
country: Belgium
facility: Research Site
city: Erpent
country: Belgium
facility: Research Site
city: Blumenau
country: Brazil
facility: Research Site
city: Botucatu
country: Brazil
facility: Research Site
city: Florianópolis
country: Brazil
facility: Research Site
city: Maringa
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Porto Alegre
country: Brazil
facility: Research Site
city: Santo Andre
country: Brazil
facility: Research Site
city: Sao Bernardo do Campo
country: Brazil
facility: Research Site
city: Sao Paulo
country: Brazil
facility: Research Site
city: Sorocaba
country: Brazil
facility: Research Site
city: Kozloduy
country: Bulgaria
facility: Research Site
city: Ruse
country: Bulgaria
facility: Research Site
city: Stara Zagora
country: Bulgaria
facility: Research Site
city: Calgary
country: Canada
facility: Research Site
state: Alberta
city: St. John's
country: Canada
facility: Research Site
state: NF
city: Ajax
country: Canada
facility: Research Site
state: Ontario
city: Barrie
country: Canada
facility: Research Site
state: Ontario
city: Sarnia
country: Canada
facility: Research Site
state: Ontario
city: Stouffville
country: Canada
facility: Research Site
state: Ontario
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Montreal
country: Canada
facility: Research Site
state: Quebec
city: Saskatoon
country: Canada
facility: Research Site
state: Saskatchewan
city: Chicoutimi
country: Canada
facility: Research Site
city: Quebec
country: Canada
facility: Research Site
city: Quebec
country: Canada
facility: Research Site
city: Quebec
country: Canada
facility: Research Site
city: Curico
country: Chile
facility: Research Site
city: Quillota
country: Chile
facility: Research Site
city: Santiago
country: Chile
facility: Research Site
city: Santiago
country: Chile
facility: Research Site
city: Santiago
country: Chile
facility: Research Site
city: Santiago
country: Chile
facility: Research Site
city: Talca
country: Chile
facility: Research Site
city: Baotou
country: China
facility: Research Site
city: Beijing
country: China
facility: Research Site
city: Beijing
country: China
facility: Research Site
city: Changsha
country: China
facility: Research Site
city: Changsha
country: China
facility: Research Site
city: Changsha
country: China
facility: Research Site
city: Chengdu
country: China
facility: Research Site
city: Chongqing
country: China
facility: Research Site
city: Ganzhou
country: China
facility: Research Site
city: Guangzhou
country: China
facility: Research Site
city: Guiyang
country: China
facility: Research Site
city: Haikou
country: China
facility: Research Site
city: Hebei
country: China
facility: Research Site
city: Hefei
country: China
facility: Research Site
city: Hohhot
country: China
facility: Research Site
city: Hohhot
country: China
facility: Research Site
city: Linhai
country: China
facility: Research Site
city: Nanchang
country: China
facility: Research Site
city: Shanghai
country: China
facility: Research Site
city: Shanghai
country: China
facility: Research Site
city: Shanghai
country: China
facility: Research Site
city: Shenzhen
country: China
facility: Research Site
city: Suzhou
country: China
facility: Research Site
city: Urumqi
country: China
facility: Research Site
city: Wenzhou
country: China
facility: Research Site
city: Wuhan
country: China
facility: Research Site
city: Wuhan
country: China
facility: Research Site
city: Xi'an
country: China
facility: Research Site
city: Yinchuan
country: China
facility: Research Site
city: Zhanjiang
country: China
facility: Research Site
city: Zhengzhou
country: China
facility: Research Site
city: Barranquilla
country: Colombia
facility: Research Site
city: Cali
country: Colombia
facility: Research Site
city: Floridablanca
country: Colombia
facility: Research Site
city: Medellin
country: Colombia
facility: Research Site
city: Pereira
country: Colombia
facility: Research Site
city: Zipaquira
country: Colombia
facility: Research Site
city: Brandys nad Labem
country: Czechia
facility: Research Site
city: Jindrichuv Hradec
country: Czechia
facility: Research Site
city: Ostrava
country: Czechia
facility: Research Site
city: Rokycany
country: Czechia
facility: Research Site
city: Teplice
country: Czechia
facility: Research Site
city: Hvidovre
country: Denmark
facility: Research Site
city: København NV
country: Denmark
facility: Research Site
city: Odense C
country: Denmark
facility: Research Site
city: Roskilde
country: Denmark
facility: Research Site
city: Vejle
country: Denmark
facility: Research Site
city: Ålborg
country: Denmark
facility: Research Site
city: Bamberg
country: Germany
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Darmstadt
country: Germany
facility: Research Site
city: Hamburg
country: Germany
facility: Research Site
city: Hannover
country: Germany
facility: Research Site
city: Koblenz
country: Germany
facility: Research Site
city: Köln
country: Germany
facility: Research Site
city: Leipzig
country: Germany
facility: Research Site
city: Leipzig
country: Germany
facility: Research Site
city: Leipzig
country: Germany
facility: Research Site
city: Marburg
country: Germany
facility: Research Site
city: Neu-Isenburg
country: Germany
facility: Research Site
city: Peine
country: Germany
facility: Research Site
city: Potsdam
country: Germany
facility: Research Site
city: Rheine
country: Germany
facility: Research Site
city: Warendorf
country: Germany
facility: Research Site
city: Athens
country: Greece
facility: Research Site
city: Exohi Thessaloniki
country: Greece
facility: Research Site
city: Ioannina
country: Greece
facility: Research Site
city: Thessaloniki
country: Greece
facility: Research Site
city: Thessaloniki
country: Greece
facility: Research Site
city: Balassagyarmat
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Edelény
country: Hungary
facility: Research Site
city: Encs
country: Hungary
facility: Research Site
city: Gödöllő
country: Hungary
facility: Research Site
city: Hajdúnánás
country: Hungary
facility: Research Site
city: Komárom
country: Hungary
facility: Research Site
city: Pécs
country: Hungary
facility: Research Site
city: Siófok
country: Hungary
facility: Research Site
city: Szeged
country: Hungary
facility: Research Site
city: Százhalombatta
country: Hungary
facility: Research Site
city: Törökbálint
country: Hungary
facility: Research Site
city: Calicut
country: India
facility: Research Site
city: Coimbatore
country: India
facility: Research Site
city: Guntur
country: India
facility: Research Site
city: Hyderabad
country: India
facility: Research Site
city: Jaipur
country: India
facility: Research Site
city: Thane
country: India
facility: Research Site
city: Vijayawada
country: India
facility: Research Site
city: Cona
country: Italy
facility: Research Site
city: Genoa
country: Italy
facility: Research Site
city: Milano
country: Italy
facility: Research Site
city: Milano
country: Italy
facility: Research Site
city: Napoli
country: Italy
facility: Research Site
city: Reggio Emilia
country: Italy
facility: Research Site
city: Roma
country: Italy
facility: Research Site
city: Rozzano
country: Italy
facility: Research Site
city: Chuo-ku
country: Japan
facility: Research Site
city: Chuo-ku
country: Japan
facility: Research Site
city: Fukuoka-shi
country: Japan
facility: Research Site
city: Himeji-shi
country: Japan
facility: Research Site
city: Hitachinaka-shi
country: Japan
facility: Research Site
city: Joyo-shi
country: Japan
facility: Research Site
city: Kawachinagano-shi
country: Japan
facility: Research Site
city: Kishiwada-shi
country: Japan
facility: Research Site
city: Kobe-shi
country: Japan
facility: Research Site
city: Koto-ku
country: Japan
facility: Research Site
city: Kure-shi
country: Japan
facility: Research Site
city: Matsusaka-shi
country: Japan
facility: Research Site
city: Mizunami-shi
country: Japan
facility: Research Site
city: Nagaoka-shi
country: Japan
facility: Research Site
city: Nagoya-shi
country: Japan
facility: Research Site
city: Nishinomiya-shi
country: Japan
facility: Research Site
city: Okayama-shi
country: Japan
facility: Research Site
city: Osaka-shi
country: Japan
facility: Research Site
city: Sagamihara-shi
country: Japan
facility: Research Site
city: Sakai-shi
country: Japan
facility: Research Site
city: Sakaide-shi
country: Japan
facility: Research Site
city: Seto-shi
country: Japan
facility: Research Site
city: Shinagawa-ku
country: Japan
facility: Research Site
city: Shinagawa-ku
country: Japan
facility: Research Site
city: Toshima-ku
country: Japan
facility: Research Site
city: Toshima-ku
country: Japan
facility: Research Site
city: Toshima-ku
country: Japan
facility: Research Site
city: Toyonaka-shi
country: Japan
facility: Research Site
city: Ueda-shi
country: Japan
facility: Research Site
city: Yanagawa-shi
country: Japan
facility: Research Site
city: Yokohama-shi
country: Japan
facility: Research Site
city: Daegu
country: Korea, Republic of
facility: Research Site
city: Jeonju-si
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Wonju-si
country: Korea, Republic of
facility: Research Site
city: Guadalajara
country: Mexico
facility: Research Site
city: Guadalajara
country: Mexico
facility: Research Site
city: Guadalajara
country: Mexico
facility: Research Site
city: Mérida
country: Mexico
facility: Research Site
city: Veracruz
country: Mexico
facility: Research Site
city: Breda
country: Netherlands
facility: Research Site
city: Leeuwarden
country: Netherlands
facility: Research Site
city: Auckland
country: New Zealand
facility: Research Site
city: Auckland
country: New Zealand
facility: Research Site
city: Christchurch
country: New Zealand
facility: Research Site
city: Dunedin
country: New Zealand
facility: Research Site
city: Hamilton
country: New Zealand
facility: Research Site
city: Iloilo City
country: Philippines
facility: Research Site
city: Los Baños
country: Philippines
facility: Research Site
city: Marilao
country: Philippines
facility: Research Site
city: Quezon City
country: Philippines
facility: Research Site
city: Białystok
country: Poland
facility: Research Site
city: Chęciny
country: Poland
facility: Research Site
city: Grodzisk Mazowiecki
country: Poland
facility: Research Site
city: Katowice
country: Poland
facility: Research Site
city: Ostrowiec Świętokrzyski
country: Poland
facility: Research Site
city: Poznań
country: Poland
facility: Research Site
city: Poznań
country: Poland
facility: Research Site
city: Proszowice
country: Poland
facility: Research Site
city: Rzeszów
country: Poland
facility: Research Site
city: Warszawa
country: Poland
facility: Research Site
city: Wieluń
country: Poland
facility: Research Site
city: Łódź
country: Poland
facility: Research Site
city: Barcelona
country: Spain
facility: Research Site
city: Hospitalet de Llobregat(Barcel
country: Spain
facility: Research Site
city: Laredo
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Málaga
country: Spain
facility: Research Site
city: Santander
country: Spain
facility: Research Site
city: Göteborg
country: Sweden
facility: Research Site
city: Göteborg
country: Sweden
facility: Research Site
city: Lund
country: Sweden
facility: Research Site
city: Malmö
country: Sweden
facility: Research Site
city: Stockholm
country: Sweden
facility: Research Site
city: Adana
country: Turkey
facility: Research Site
city: Istanbul
country: Turkey
facility: Research Site
city: İstanbul
country: Turkey
facility: Research Site
city: Izmir
country: Turkey
facility: Research Site
city: Kocaeli
country: Turkey
facility: Research Site
city: Mersin
country: Turkey
facility: Research Site
city: Barnsley
country: United Kingdom
facility: Research Site
city: Birmingham
country: United Kingdom
facility: Research Site
city: Blackpool
country: United Kingdom
facility: Research Site
city: Bradford
country: United Kingdom
facility: Research Site
city: Chertsey
country: United Kingdom
facility: Research Site
city: Cottingham
country: United Kingdom
facility: Research Site
city: Leicester
country: United Kingdom
facility: Research Site
city: Manchester
country: United Kingdom
facility: Research Site
city: Oxford
country: United Kingdom
facility: Research Site
city: Perth
country: United Kingdom
facility: Research Site
city: Southampton
country: United Kingdom
facility: Research Site
city: Stockton-on-Tees
country: United Kingdom
facility: Research Site
city: Wishaw
country: United Kingdom
facility: Research Site
city: Hanoi
country: Vietnam
facility: Research Site
city: Ho Chi Minh city
country: Vietnam
facility: Research Site
city: Ho Chi Minh
country: Vietnam
facility: Research Site
Study officials:
affiliation: Temple University School of Medicine, 3401 North Broad Street, Suite 745 PP, Philadelphia, PA 19140
name: Gerard Criner, MD
role: PRINCIPAL_INVESTIGATOR
References: